Due to the increased need for cost-efficient procedures and the pressure on public expenditure, the European market for pharmaceutical products is less dynamic than in the past. This high-technology sector is faced with the following challenges: austerity measures introduced by European governments, rapid growth in the market and research in emerging economies, and migration of economic, research and development activities outside of Europe.